OVERDOSE RESPONSE CENTER

Delaware Street Drug Report

April 2025

#2025-02

Disclaimer: This report is for harm reduction and educational purposes only and should not be used for professional or publication use. The data included is from sporadic drug residue testing across various locations in Delaware and should not be generalized. Stamp names are not universal or consistent in the street supply and are provided here for reference only. The selected stamps below are from samples collected during **March 2025**.

Select Stamps	Compounds Detected						
Great Value	4-ANPP	Diphenhydramine	Fentanyl	Medetomidine	***Pregabalin**	Tetracaine	
Great Value	4-ANPP	Cocaine	Diphenhydramine	Fentanyl	Medetomidine	***Pregabalin**	Tetracaine
Newport	Fentanyl	Medetomidine	***Pregabalin**				
Newport	***BTMPS**	Ethyl 4-ANPP	Fentanyl	Medetomidine	Tetracaine		
Hey Yes	Fentanyl	Medetomidine					
Hey Yes	4-ANPP	Fentanyl	Medetomidine	***Pregabalin**	Tetracaine		
Hey Yes	4-ANPP	Cocaine	Fentanyl	Medetomidine	***Pregabalin**		
The Arrow	4-ANPP	Fentanyl	Medetomidine	***Pregabalin**	Tetracaine		
Block Rock	4-ANPP	Fentanyl	Medetomidine	***Pregabalin**	Tetracaine		
Block Rock	4-ANPP	Cocaine	Fentanyl	Medetomidine	***Pregabalin**		
Bossman	4-ANPP	Fentanyl	Heroin	Lidocaine	Medetomidine	Tetracaine	Xylazine
Bossman	Cocaine	Gabapentin					
Donald Trump	***BTMPS**	Fentanyl	Medetomidine	Tetracaine			
2k	4-ANPP	Fentanyl	Heroin	Lidocaine	Mannitol	Medetomidine	Xylazine
BMW	Cocaine	Fentanyl	Heroin	Lidocaine	Medetomidine	Tetracaine	Xylazine

*Emerging Substances:

BTMPS (Tinuvin®)

BTMPS is an industrial chemical not intended for use in humans or animals. It is used as a protective coating in plastics to prevent breakdown from UV rays. At this time, side effects from BTMPS in humans are not well known.

Pregabalin (Lyrica®)

Pregabalin is commonly used to treat nerve pain (fibromyalgia). As a prescription medication, there are known adverse side effects and negative drug interactions to consider, including respiratory depression.

DELAWARE DEPARTMENT OF HEALTH AND SOCIAL SERVICES
DIVISION OF SUBSTANCE ABUSE AND MENTAL HEALTH

Contact: ORC@delaware.gov

Approved: 17 April 2025


OVERDOSE RESPONSE CENTER

Delaware Street Drug Report

April 2025

#2025-02

Trending Substances



- In March, fentanyl and medetomidine was still the most common drug combination, while xylazine continued to decline.
- There was a significant increase in the number of samples collected in March. With many samples containing primarily stimulants (cocaine and methamphetamine), the overall percentage of samples with fentanyl was lower. This does **NOT** indicate a decrease of fentanyl in the drug supply, just a more diverse sampling.

Compound Detected	Oct-24 (36 samples)	Nov-24 (68 samples)	Dec-24 (46 samples)	Jan-25 (12 samples)	Feb-25 (13 samples)	Mar-25 (106 samples)
Xylazine	14%	44%	35%	25%	23%	14%
Medetomidine	64%	69%	72%	83%	92%	68%
Fentanyl	75%	78%	85%	83%	92%	70%
Tetracaine	64%	56%	57%	75%	62%	42%
Procaine	19%	22%	15%	33%	8%	16%
Lidocaine	22%	31%	37%	33%	23%	22%
4-ANPP	31%	37%	35%	42%	77%	46%
BTMPS	17%	28%	33%	25%	31%	15%
Fluorofentanyl	6%	7%	0%	33%	15%	4%
Cocaine	17%	18%	7%	17%	15%	25%
Methamphetamine	0%	1%	0%	0%	0%	11%
Pregabalin	0%	0%	0%	0%	31%	20%
Heroin	0%	3%	0%	0%	8%	9%
Carfentanyl	0%	0%	0%	0%	0%	0%
Levamisole	0%	0%	0%	0%	0%	0%
Bromazolam	0%	1%	0%	0%	0%	0%

DELAWARE DEPARTMENT OF HEALTH AND SOCIAL SERVICES
DIVISION OF SUBSTANCE ABUSE AND MENTAL HEALTH

Contact: ORC@delaware.gov

Approved: 17 April 2025